Related Experiment Videos
Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic
D Claxton1, H Kantarjian, R Kurzrock
1Department of Clinical Immunology and Biological Therapy, University of Texas M.D. Anderson Cancer Center, Houston.
Acta Haematologica
|January 1, 1990
Abstract:
A patient whose chronic myelogenous leukemia (CML) was treated with interferon alpha (IFN-alpha) is described. The disease showed karyotypic evolution during the chronic phase and the later myeloid acceleration. Both of these secondary clonal phenomena responded to IFN-alpha dose escalation. The case illustrates the dose dependence of CML responses to IFN-alpha. The phenomenon of clonal evolution is discussed in the context of this patient's disease.